ClinicalTrials.gg
RecruitingNCT05629494ADAPT-PSAUpdated Oct 18, 2024

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test

A Phase 4 interventional study of Ibuprofen 400 mg, TID and PSA test in Prostate Cancer, Prostate Inflammation and PSA, sponsored by Albany Medical College. Recruiting at 3 sites in United States. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-10-18.

Sponsored by Albany Medical College · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 1 month later.
Phase
Phase 4
Study type
Interventional
Enrollment
198
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Study summary

Prostate cancer is the most frequently diagnosed cancer in men in the Unites States. Nearly 1 million prostate biopsy procedures are performed in the United States annually and elevated prostate-specific antigen (PSA) level is the primary reason for prostate biopsy in > 90% of cases. However, at the PSA levels which trigger prostate biopsy, often no cancer is found in prostate biopsy specimens. PSA test can be elevated due to reasons other than cancer such as inflammation or natural variation in the level. Investigators plan to treat men with elevated PSA level with over the counter anti-inflammatory medications (ibuprofen, naproxen) to see if the PSA level will decrease to an acceptable level.

Read the detailed description

It's known that PSA level can be elevated due to reasons other than prostate cancer including benign prostatic hypertrophy, prostatitis or other urinary tract infections, non-infectious inflammation, and physiologic variation over time. Consequently, nearly 50% of prostate biopsy procedures performed due to elevated PSA level do not yield any cancer , but still expose the patients to the risks of the procedure related complications (discomfort/pain, anxiety, bleeding, infection, and cost). Thus, measures to improve the reliability of PSA test, and potentially avoiding unnecessary procedures, are of significant importance to the patient and healthcare system.

It is common practice to check PSA level annually. PSA test results can vary over time, either due to the imprecision in the analysis and/or due to the biologic variability. This can result in an apparent rise in PSA level when no clinically meaningful rise had occurred. Its estimated that the average lab variation in PSA was approximately 6% and the average biologic variation about 14%. This, it is recommended that isolated elevation in PSA level should be confirmed after several weeks, and before proceeding with further interventions, including prostate biopsy.

Sub-clinical, histologic Inflammation (presence of inflammatory cells) within the prostate tissue and its effect on PSA level has been reported in various settings. In two population-based studies, men who were regularly using over the counter (OTC) nonsteroidal anti-inflammatory drugs (NSAIDs, e.g ibuprofen, naproxen) had lower PSA levels compared to non-users.

Currently, two strategies are utilized in clinical practice to ensure that the PSA level is truly elevated:

  1. Repeat PSA test after several weeks or
  2. A short course of OTC NSAIDs, and then repeat PSA test

Investigators propose to conduct a randomized study to determine the effect of NSAIDs on PSA level compared to the biologic variations in PSA level noted upon repeat testing.

02

Conditions studied

  • Prostate Cancer
  • Prostate Inflammation
  • PSA

Keywords

  • Prostate-specific antigen
  • PSA test
  • Prostate biopsy
  • non-steroidal anti-inflammatory drugs NSAIDS
03

In context

Prostatic Neoplasms

7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.

This study's planned enrollment of 198 is above the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.

Browse Prostatic Neoplasms studies →

Lead sponsor

Albany Medical College is the lead sponsor of 81 studies on the registry; 14 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male patients age between 18-80 years old with a screening PSA > 3 ng/ml being considered for additional diagnostic testing (e.g., MRI, )
  • Normal digital rectal examination within the past two years. A documented normal digital rectal examination by another physician or advanced practice provider (NP, PA, etc) is acceptable.
  • No clinical symptoms concerning for acute urinary tract infection (e.g. dysuria, malodorous urine, positive urine culture)

Exclusion criteria

Exclusion Criteria:

  • History of or allergy to ibuprofen or NSAIDs.
  • History of peptic ulcer disease, GI bleeding or NSAIDs induced GI adverse events
  • Known bleeding disorders
  • Known severe chronic kidney disease: \< 30 mL/min/1.73 m2
  • Heart failure, significant heart disease
  • Poorly controlled hypertension
  • Active urinary tract infections or bacteriuria
  • Concomitant use of 5-alpha reductase inhibitors (finasteride, dutasteride) unless patient has been taking it for at least 6 months
  • Known prostate cancer or underwent prostate MRI or in the last year
  • Urinary tract instrumentation in the past 6 weeks (catheter, cystoscopy)
  • Concomitant anti-inflammatory or steroidal drugs
  • Concomitant dual-antiplatelet or anticoagulant therapy use except aspirin 81 mg alone
  • Know history of severe liver disease determined by abnormal liver function tests (elevated or ALT > 3X based on exiting history or labs)
  • Any other medical to NSAIDs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
198 participants (estimated)

Study arms

  • Active comparator
    Repeat serum PSA test

    Repeat PSA test at 6 (± 1) weeks, without any treatment

    Diagnostic Test: PSA test

  • Experimental
    Treatment with NSAIDS

    Treatment with Ibuprofen 400 mg, 3 times per day, then repeat PSA test at 6 (± 1) weeks

    Drug: Ibuprofen 400 mg, TID · Diagnostic Test: PSA test

Interventions

  • Participants will receive Ibuprofen 400 mg 3 times per day for 10 days.

    Also known as: Motrin

  • Diagnostic testPSA test

    PSA test will be repeated in 6 weeks

06

What researchers measure

Primary outcomes

  1. Difference in the extent of changes in PSA level between the study groups

    Difference in PSA levels, within and between groups

    Time frame: 6 weeks

  2. Participants with change in PSA level to below the age-specific PSA threshold

    To determine if changes in PSA level were sufficient to avoid intervention

    Time frame: 6 weeks

Secondary outcomes

  1. Determine the incidence of acute kidney injury following a short course of ibuprofen

    To determine if the treatment and PSA changes correlates with change in urinary symptoms

    Time frame: 1 year

  2. Durability of the change in PSA levels

    Serial PSA levels will be examined to determine whether the change in PSA level is transient or durable

    Time frame: 1 to 1.5 year

  3. Changes in voiding symptoms as measured by the International Prostate Symptom Score

    Patient reported symptom score, ranging from 0-35 (higher score=worse outcome)

    Time frame: 3-12 months

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05629494
Lead sponsor
Albany Medical College
Responsible party
Badar M. Mian (Professor of Urology, Albany Medical College) — Principal investigator
First posted
Nov 29, 2022
Start date
Sep 27, 2022
Primary completion
Mar 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 18, 2024

Study contacts

Brenda Romeo
Contact
amcurologyresearch@amc.edu
518-262-8579
Badar Mian, MD
principal investigator · Albany Medical College
Jay Raman, MD
principal investigator · Penn State Health
Scott Eggener, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion